Efficacy of Pegylated Interferon Plus Ribavirin Plus Nitazoxanide in HCV Genotype 4 and HIV Coinfection

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Spanish National Health System
Information provided by (Responsible Party):
Juan Macías, Andaluz Health Service
ClinicalTrials.gov Identifier:
NCT01529073
First received: February 5, 2012
Last updated: February 6, 2012
Last verified: February 2012

February 5, 2012
February 6, 2012
February 2012
December 2014   (final data collection date for primary outcome measure)
Sustained virological response [ Time Frame: 24 weeks after finishing the scheduled treatment ] [ Designated as safety issue: No ]
The proportion of patients with HCV RNA ≤10 IU/ml 24 weeks after finishing the programmed length of treatment (52 weeks).
Same as current
Complete list of historical versions of study NCT01529073 on ClinicalTrials.gov Archive Site
Safety of Peg-interferon plus ribavirin plus nitazoxanide [ Time Frame: Every 4 weeks until 28 weeks of treatment, then every 8 weeks until the end of treatment (52 weeks) ] [ Designated as safety issue: Yes ]
The proportion of patients with grade 3 or 4 adverse events according to the WHO classification.
Same as current
Not Provided
Not Provided
 
Efficacy of Pegylated Interferon Plus Ribavirin Plus Nitazoxanide in HCV Genotype 4 and HIV Coinfection
Phase II Clinical Trial to Evaluate the Antiviral Activity of Pegylated Interferon Plus Ribavirin Plus Nitazoxanide in Individuals With Chronic Hepatitis Due to HCV Genotype 4 and Coinfected by HIV

Objectives: 1. Primary objective: To Evaluate the rate of sustained virological response (SVR) of pegylated interferon alfa-2b (Peg-IFN) plus ribavirin (RBV) plus nitazoxanide (NTZ) in patients coinfected by HIV and HCV genotype 4 (HCV-4), never treated before (naïve) and with a treatment failure to a standard therapy with Peg-IFN plus RBV (experienced), and to compare it with the rate of SVR of these patients with Peg-IFN plus RBV is a historical cohort. 2. Secondary objectives: In naive, as well as in experienced patients: a) To evaluate the virological activity at weeks 4 and 12 after starting the combination of Peg-IFN plus RBV plus NTZ in HIV/HCV-4-coinfected patients. b) To analyze the safety of Peg-IFN plus RBV plus NTZ in HIV/HCV-4-coinfected patients.

Design: Pilot clinical trial without control to evaluate efficacy and safety (phase II).

Patients: Individuals with HIV infection and with confirmed chronic HCV infection.

Treatment: NTZ 500 mg every 12 hours during 4 weeks, followed by NTZ 500 mg every 12 hours plus Peg-IFN plus weigh-adjusted RBV for 48 weeks. Total duration of therapy: 52 weeks.

Primary variable: The proportion of patients with HCV RNA ≤10 IU/ml 24 weeks after finishing the programmed length of treatment.

Secondary variables: 1. The frequency of individuals with HCV RNA ≤10 IU/ml 12 weeks after finishing the programmed length of treatment. 2. The proportion of patients with HCV RNA ≤10 IU/ml at 4 and 12 weeks after adding PegIFN plus RBV to NTZ. 3. The frequency of severe adverse events.

Main Objective To evaluate the SVR rate of treatment with Peg-IFN alfa-2b plus RBV and NTZ in patients coinfected with HIV and HCV genotype 4, both never exposed to therapy against HCV or who failed a previous treatment with Peg-IFN plus RBV, and to compare with the SVR rate obtained in patients with Peg-IFN plus RBV in a historical cohort.

Secondary objectives: In naive, as well as in experienced patients:

  1. To evaluate the virological activity at weeks 4 and 12 after starting the combination of Peg-IFN plus RBV plus NTZ in HIV/HCV-4-coinfected patients.
  2. To analyze the safety of Peg-IFN plus RBV plus NTZ in HIV/HCV-4-coinfected patients.

Design Single arm pilot clinical trial to evaluate safety and efficacy (phase II).

Disease or disorder under study Coinfection with HIV and HCV genotype 4.

Drugs under study Nitazoxanide 500 mg every 12 hours for 4 weeks followed by nitazoxanide 500 mg every 12 hours plus pegylated interferon alfa-2b 1.5 mcg/kg/week and weight-adjusted ribavirin for 48 weeks.

Study Population and total number of subjects Patients infected with HIV-1 with chronic HCV genotype 4 who meet the selection criteria.

Number of patients included in the study: 45.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • HCV Coinfection
  • HIV Infection
Drug: Nitazoxanide
Nitazoxanide 500 mg bid po for 4 weeks, followed by nitazoxanide 500 mg bid plus pegylated interferon alpha 2b 1.5 mg/kg/week sc plus weight-adjusted ribavirin po for 48 weeks.
Other Names:
  • Alinia
  • Annita
  • Daxon
  • Dexidex
  • Kidonax
  • Mitafar
  • Pacovanton
  • Paramix
  • Nitax
  • Zox
  • Nitazox
  • Niazid
  • Toza
Experimental: Nitazoxanide
Intervention: Drug: Nitazoxanide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
45
February 2015
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. HIV infection.
  2. Infection with HCV genotype 4.
  3. No prior treatment with any interferon or no response to a previous treatment with Peg-IFN plus RBV. The lack of response will include both nonresponders, and those who showed relapse.
  4. Stable antiretroviral therapy 24 weeks before starting the study drugs, with undetectable plasma HIV RNA during that period of time.
  5. Commitment to use two non-hormonal contraception during the study and up to 24 weeks after treatment.
  6. Acceptance to give written informed consent to participate in the trial.

Exclusion Criteria:

  1. Antiretroviral therapy including didanosine, stavudine, zidovudine and abacavir.
  2. Decompensated cirrhosis.
  3. Presence of other significant liver diseases, including chronic hepatitis or acute hepatitis B, acute hepatitis hepatitis A, hemochromatosis or deficiency of alpha-1 antitrypsin.
  4. Pregnancy and lactation.
  5. Men planning pregnancy with their partners during the study and up to 24 weeks after treatment.
  6. Active or uncontrolled depression, other psychiatric illness, or disease during the previous year which may, in the investigator's opinion, prevent participation in the study.
  7. Previous suicide attempt.
  8. Active thyroid disease or poorly controlled with treatment.
  9. Previous autoimmune diseases such as inflammatory bowel disease, psoriasis serious, or rheumatoid arthritis, which may be exacerbated by interferon.
  10. Chemotherapy or immunomodulatory 24 weeks before starting the study.
  11. Serious illness, including cancer or unstable coronary disease, 24 weeks before starting the study.
  12. Any chronic disease which, in the opinion of the investigator, may prevent complete the study.
  13. Presence of acute or active opportunistic infections 48 weeks before starting the study.
  14. Evidence of hepatocellular carcinoma or alpha-fetoprotein levels ≥ 50 ng / ml, unless an imaging technique shows no evidence of liver tumor, all obtained 24 weeks before starting the study.
  15. Hemoglobinopathy or other conditions that may facilitate hemolysis.
  16. Solid organ or bone marrow transplant.
  17. Known hypersensitivity to any of the drugs under study.
  18. Active consumption of drugs or alcohol in the opinion of the investigator would interfere with participation in the study. The use of methadone or other opiate replacement therapy is not considered an exclusion criterion.
  19. Serious side effects from treatment with Peg-IFN plus RBV in patients with prior failure of such treatment.
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01529073
NTZSPA001, 2010-024336-42
Yes
Juan Macías, Andaluz Health Service
Juan Macías
Spanish National Health System
Principal Investigator: Juan Macías, MD, PhD Infectious Diseases and Microbiology Unit. Hospital Universitario de Valme. Servicio Andaluz de Salud
Andaluz Health Service
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP